Christopher Lock
Christopher Lock
Clinical Associate Professor, Stanford University
Verified email at - Homepage
Cited by
Cited by
Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis
C Lock, G Hermans, R Pedotti, A Brendolan, E Schadt, H Garren, ...
Nature medicine 8 (5), 500-508, 2002
The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease
D Chabas, SE Baranzini, D Mitchell, CCA Bernard, SR Rittling, ...
Science 294 (5547), 1731-1735, 2001
Inhibitory role for GABA in autoimmune inflammation
R Bhat, R Axtell, A Mitra, M Miranda, C Lock, RW Tsien, L Steinman
Proceedings of the National Academy of Sciences 107 (6), 2580-2585, 2010
Gene microarray identification of redox and mitochondrial elements that control resistance or sensitivity to apoptosis
DW Voehringer, DL Hirschberg, J Xiao, Q Lu, M Roederer, CB Lock, ...
Proceedings of the National Academy of Sciences 97 (6), 2680-2685, 2000
Expression of HLA-DR4 and human CD4 transgenes in mice determines the variable region beta-chain T-cell repertoire and mediates an HLA-DR-restricted immune response
L Fugger, SA Michie, I Rulifson, CB Lock, GS McDevitt
Proceedings of the National Academy of Sciences 91 (13), 6151-6155, 1994
Janus-like opposing roles of CD47 in autoimmune brain inflammation in humans and mice
MH Han, DH Lundgren, S Jaiswal, M Chao, KL Graham, CS Garris, ...
Journal of Experimental Medicine 209 (7), 1325-1334, 2012
Response to comment on" The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease"
L Steinman, S Youssef, N Van Venrooij, D Chabas, SE Baranzini, ...
Science 299 (5614), 1845-1845, 2003
Minimum structural requirements for peptide presentation by major histocompatibility complex class II molecules: implications in induction of autoimmunity.
AM Gautam, CB Lock, DE Smilek, CI Pearson, L Steinman, HO McDevitt
Proceedings of the National Academy of Sciences 91 (2), 767-771, 1994
MHC class II sequences of an HLA-DR2 narcoleptic
CB Lock, AKL So, KI Welsh, JD Parkes, J Trowsdale
Immunogenetics 27 (6), 449-455, 1988
Immune factors in narcolepsy
N Langdon, C Lock, K Lock, D Lock, R Lock, H Lock, D Lock, JD Jones
Sleep 9 (1), 143-148, 1986
Analysis of HLA-DR glycoproteins by DNA-mediated gene transfer. Definition of DR2 beta gene products and antigen presentation to T cell clones from leprosy patients.
D Wilkinson, RR De Vries, JA Madrigal, CB Lock, JP Morgenstern, ...
The Journal of experimental medicine 167 (4), 1442-1458, 1988
Selegiline in narcolepsy
SE Roselaar, N Langdon, CB Lock, P Jenner, JD Parkes
Sleep 10 (5), 491-495, 1986
The role of TNFα and lymphotoxin in demyelinating disease
C Lock, J Oksenberg, L Steinman
Annals of the rheumatic diseases 58 (suppl 1), I121-I128, 1999
Antigen Recognition and Peptide‐Mediated Immunotherapy in Autoimmune Disease
DE Smilek, CB Lock, HO Mcdevitt
Immunological reviews 118 (1), 37-71, 1990
Narcolepsy and immunity.
JD Parkes, N Langdon, C Lock
British medical journal (Clinical research ed.) 292 (6517), 359, 1986
Prevention of insulin-dependent diabetes mellitus in nonobese diabetic mice by immunogenic but not by tolerated peptides.
M Vaysburd, C Lock, H McDevitt
The Journal of experimental medicine 182 (3), 897-902, 1995
Gene microarray analysis of multiple sclerosis lesions
CB Lock, RA Heller
Trends in molecular medicine 9 (12), 535-541, 2003
The specificity of the antibody response in multiple sclerosis
H Garren, L Steinman, C Lock
Annals of neurology 43 (1), 4-6, 1998
Genetic factors in sleep disorders.
JD Parkes, CB Lock
Journal of Neurology, Neurosurgery & Psychiatry 52 (Suppl), 101-108, 1989
Competitive inhibition of antigen presentation in animal models of autoimmune disease.
C Lock, D Smilek, A Gautam, M Vaysburd, S Dwivedy, H McDevitt
Seminars in immunology 3 (4), 247-255, 1991
The system can't perform the operation now. Try again later.
Articles 1–20